Nektar Therapeutics | NKTR - Assets


Nektar Therapeutics reported $763.27M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 96.05B 409M Sep/2026
Baxter International USD 19.41B 377M Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cipla INR 434.34B 9.38B Sep/2026
Dr.Reddys Laboratories INR 576.31B 1.01B Sep/2026
Eisai JPY 1.52T 33.49B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Exelixis USD 2.51B 19.26M Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 318.68M 26.72M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Takeda JPY 15.27T 391.77B Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
Xencor USD 770.5M 45.54M Sep/2026